News
It is estimated that over 50% of OA patients do not follow the treatment prescribed to them. Pharmacotherapeutical follow-up, healthcare awareness and involvement of pharmacists, are key to achieve a better monitoring of these chronic patients.
Vitafoods Europe organization selected Bioibericas new ingredient Mobilee® to take an important part in the event.
The results show that this drug combination significantly improves a patient’s pain, disability, rigidity, inflammation, joint effusion, and overall quality of life.There was a roughly 50% improvement in pain and functional disability. Any improvement in excess of 20% is considered clinically significant.
The results show that this drug combination significantly improves a patients pain, disability, rigidity, inflammation, joint effusion, and overall quality of life.There was a roughly 50% improvement in pain and functional disability. Any improvement in excess of 20% is considered clinically significant.
Bioberica Farma has launched DUARTRON, the only glucosamine on the market sold in hard gelatine capsules, a dosage form preferred by patients because of its ease of use. Furthermore, Duartron® is funded by the Spanish National Health System. Osteoarthritis is a disease affecting a large percentage of the population. In Spain, for instance, is the third most common chronic disease.